Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA's Graham To Present Overview At COX-2 Advisory Committee Meeting

This article was originally published in The Pink Sheet Daily

Executive Summary

Office of Drug Safety Director for Science & Medicine David Graham is scheduled to present an "epidemiological overview" on Feb. 16, day one of the three-day meeting. Senate Finance Committee Chairman Charles Grassley is concerned that FDA has forbidden Graham from discussing certain data.

You may also be interested in...



Celebrex Has No Apparent MI Signal At 200 Mg Or Less, FDAer Graham Says

The drug safety officer's meta-analysis suggests that Celebrex and Bextra can both be safely marketed at low doses, but Vioxx poses a risk at both the 25 mg and 50 mg doses. At committee meeting, Graham discusses results of two unpublished studies, which he says he was initially told by FDA not to present.

FDA To Act On COX-2 Committee Input Within "Next Few Weeks"

In remarks to the Arthritis Drugs/Drug Safety & Risk Management advisory committee meeting, CDER Acting Director Galson says the agency will take "rapid" action on the panel's recommendations.

Celebrex Has No Apparent MI Signal At 200 Mg Or Less, FDAer Graham Says

The drug safety officer's meta-analysis suggests that Celebrex and Bextra can both be safely marketed at low doses, but Vioxx poses a risk at both the 25 mg and 50 mg doses. At committee meeting, Graham discusses results of two unpublished studies, which he says he was initially told by FDA not to present.

Topics

UsernamePublicRestriction

Register

LL1129949

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel